A 2025 Biogerontology study replicated the central laboratory finding that the AEDG tetrapeptide extends telomere length in cultured human cells, keeping Epitalon on the longevity research map even as clinical evidence lags.
A 2025 study published in Biogerontology independently replicated earlier Khavinson-group findings that Epitalon, the tetrapeptide Ala-Glu-Asp-Gly, upregulates telomerase activity and extends telomere length in cultured human somatic cells. The result, reinforced in several 2026 reviews, has helped sustain research interest in the compound as an aging biology tool despite the near-total absence of modern clinical trial data.
In animal models, Epitalon administration continues to associate with 12 to 24 percent increases in median and maximum lifespan, improvements in circadian rhythm markers, and reduced tumor incidence in aged rodent cohorts. The mechanism is thought to involve direct interaction with the catalytic subunit of telomerase and modulation of pineal gland function. Longevity researchers have begun to treat Epitalon as a tractable compound for studying telomere biology rather than as a near-term clinical candidate.
The human translation remains speculative. No large-scale, peer-reviewed, double-blind clinical trial has been published, and the historical Russian cohort studies that showed mortality reductions have not been independently replicated in Western populations. The compound is sold widely in gray-market research channels, and the July 2026 FDA advisory vote included Epitalon on the list recommended for compounding — a decision that has not yet translated into formal rulemaking.
Source: Yahoo Finance Healthcare
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.